Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.57 |
| ▸ | MAP2K2 | P36507 | 18/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | BRAF | P15056 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | ACTR3 | P61158 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1488377 | 0.92 | MAP2K2 (0.69) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL30220987 | 0.92 | MAP2K2 (0.69) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL17121710 | 0.92 | MAP2K2 (0.69) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL30220939 | 0.89 | MAP2K1 (0.55) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL1488244 | 0.89 | MAP2K1 (0.55) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL18968056 | 0.87 | MAP2K2 (0.61) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL21010852 | 0.85 | MAP2K1 (0.51) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL21010529 | 0.84 | MAP2K2 (0.65) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL18931262 | 0.84 | MAP2K1 (0.72) | MAP2K1MAP2K2CHRM2CHRM1BRAF | |
| SCHEMBL6848293 | 0.83 | MAP2K1 (0.46) | MAP2K1MAP2K2CHRM2CHRM1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | EXELIXIS, INC. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166523-A9 | MEK Inhibitors And Methods Of Their Use | BRAF, NRAS, MAP3K1 | MAP2K1 51/4885MAP2K2 49/4885CHRM2 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.